The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents
Objectives. To prospectively examine the efficacy and safety of propiverine hydrochloride in patients with overactive bladder (OAB) symptoms who poorly responded to previous treatment with solifenacin, tolterodine or imidafenacin. Methods. Patients aged ≥20 with persisting OAB symptoms (≥6 in OAB sy...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2011/714978 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554323087720448 |
|---|---|
| author | Naoya Masumori Shintaro Miyamoto Taiji Tsukamoto Seiji Furuya Akihiko Iwasawa Takashi Sato Naoki Itoh Akihiko Shibuya Toshiro Oda |
| author_facet | Naoya Masumori Shintaro Miyamoto Taiji Tsukamoto Seiji Furuya Akihiko Iwasawa Takashi Sato Naoki Itoh Akihiko Shibuya Toshiro Oda |
| author_sort | Naoya Masumori |
| collection | DOAJ |
| description | Objectives. To prospectively examine the efficacy and safety of propiverine hydrochloride in patients with overactive bladder (OAB) symptoms who poorly responded to previous treatment with solifenacin, tolterodine or imidafenacin. Methods. Patients aged ≥20 with persisting OAB symptoms (≥6 in OAB symptom score (OABSS)) even after at least 4-week treatment using solifenacin, tolterodine or imidafenacin were enrolled. Propiverine 20 mg/day was administered for 12 weeks to 70 patients who desired the further improvement of OAB symptoms and 3 who had intolerable adverse events of previous drugs. The OABSS and postvoid residual urine volume (PVR) were determined before and at 4 and 12 weeks of treatment. Results. Of 73 patients enrolled (29 males and 44 females, median age 71 years), 52 completed the protocol treatment. The OABSS was significantly improved by propiverine treatment (9.0 at baseline, 6.2 at 4 weeks, 6.3 at 12 weeks (P<0.001)). The scores of OAB symptoms (nighttime frequency, urgency and urge incontinence) except daytime frequency also improved significantly. No increase in PVR was observed. The most frequent adverse event was dry mouth (13.7%), followed by constipation (6.8%). Conclusions. Propiverine is useful to improve OAB for patients who poorly respond to solifenacin, tolterodine or imidafenacin. |
| format | Article |
| id | doaj-art-de3f18a5bddc48d9a67bebe441bdee9b |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-de3f18a5bddc48d9a67bebe441bdee9b2025-02-03T05:51:50ZengWileyAdvances in Urology1687-63691687-63772011-01-01201110.1155/2011/714978714978The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic AgentsNaoya Masumori0Shintaro Miyamoto1Taiji Tsukamoto2Seiji Furuya3Akihiko Iwasawa4Takashi Sato5Naoki Itoh6Akihiko Shibuya7Toshiro Oda8Department of Urology, Sapporo Medical University School of Medicine, Sapporo 060-8543, JapanDepartment of Urology, Sapporo Medical University School of Medicine, Sapporo 060-8543, JapanDepartment of Urology, Sapporo Medical University School of Medicine, Sapporo 060-8543, JapanFuruya Hospital, Urology service, Kitami 090-0065, JapanIwasawa Clinic, Urology service, Sapporo 060-0061, JapanNisshin Urological Clinic, Urology service, Tomakomai 053-0833, JapanNTT East Japan Sapporo Hospital, Division of Urology, Sapporo 060-0061, JapanKaguraoka Urological Clinic, Urology service, Asahikawa 078-8315, JapanKiyota Urological Clinic, Urology service, Sapporo 004-0841, JapanObjectives. To prospectively examine the efficacy and safety of propiverine hydrochloride in patients with overactive bladder (OAB) symptoms who poorly responded to previous treatment with solifenacin, tolterodine or imidafenacin. Methods. Patients aged ≥20 with persisting OAB symptoms (≥6 in OAB symptom score (OABSS)) even after at least 4-week treatment using solifenacin, tolterodine or imidafenacin were enrolled. Propiverine 20 mg/day was administered for 12 weeks to 70 patients who desired the further improvement of OAB symptoms and 3 who had intolerable adverse events of previous drugs. The OABSS and postvoid residual urine volume (PVR) were determined before and at 4 and 12 weeks of treatment. Results. Of 73 patients enrolled (29 males and 44 females, median age 71 years), 52 completed the protocol treatment. The OABSS was significantly improved by propiverine treatment (9.0 at baseline, 6.2 at 4 weeks, 6.3 at 12 weeks (P<0.001)). The scores of OAB symptoms (nighttime frequency, urgency and urge incontinence) except daytime frequency also improved significantly. No increase in PVR was observed. The most frequent adverse event was dry mouth (13.7%), followed by constipation (6.8%). Conclusions. Propiverine is useful to improve OAB for patients who poorly respond to solifenacin, tolterodine or imidafenacin.http://dx.doi.org/10.1155/2011/714978 |
| spellingShingle | Naoya Masumori Shintaro Miyamoto Taiji Tsukamoto Seiji Furuya Akihiko Iwasawa Takashi Sato Naoki Itoh Akihiko Shibuya Toshiro Oda The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents Advances in Urology |
| title | The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents |
| title_full | The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents |
| title_fullStr | The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents |
| title_full_unstemmed | The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents |
| title_short | The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents |
| title_sort | efficacy and safety of propiverine hydrochloride in patients with overactive bladder symptoms who poorly responded to previous anticholinergic agents |
| url | http://dx.doi.org/10.1155/2011/714978 |
| work_keys_str_mv | AT naoyamasumori theefficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT shintaromiyamoto theefficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT taijitsukamoto theefficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT seijifuruya theefficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT akihikoiwasawa theefficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT takashisato theefficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT naokiitoh theefficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT akihikoshibuya theefficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT toshirooda theefficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT naoyamasumori efficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT shintaromiyamoto efficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT taijitsukamoto efficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT seijifuruya efficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT akihikoiwasawa efficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT takashisato efficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT naokiitoh efficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT akihikoshibuya efficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents AT toshirooda efficacyandsafetyofpropiverinehydrochlorideinpatientswithoveractivebladdersymptomswhopoorlyrespondedtopreviousanticholinergicagents |